Canaccord Genuity Reiterates a 'Buy' on Solazyme (SZYM); Encouraged by Management’s Execution
SZYM Hot Sheet
Rating Summary:8 Buy, 0 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on Solazyme (NASDAQ: SZYM) price target of $19.00.
Analyst, John Quealy, said, "We come away encouraged by management’s execution on milestones thus far. Algenist continues to gain traction (and experience) and drive near-term product revenues, while the Street looks for the formalization of the Bunge JV this year and related plant groundbreaking (’13) as key events signaling the progression of planned capacity additions."
"SZYM reported Q4/11 revenue/GAAP EPS of $14.9M/$(0.26) vs. our modeled $15.0M/$(0.16) and consensus at $15.1M/$(0.16). We note that heavier than expected R&D expense largely accounted for the EPS variance (~$0.09 headwind). We continue to find financial results to be less meaningful than progress vs. key milestones at this point."
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $11.87 yesterday, with a 52 week range of $7.68-$27.47.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, John Quealy, said, "We come away encouraged by management’s execution on milestones thus far. Algenist continues to gain traction (and experience) and drive near-term product revenues, while the Street looks for the formalization of the Bunge JV this year and related plant groundbreaking (’13) as key events signaling the progression of planned capacity additions."
"SZYM reported Q4/11 revenue/GAAP EPS of $14.9M/$(0.26) vs. our modeled $15.0M/$(0.16) and consensus at $15.1M/$(0.16). We note that heavier than expected R&D expense largely accounted for the EPS variance (~$0.09 headwind). We continue to find financial results to be less meaningful than progress vs. key milestones at this point."
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $11.87 yesterday, with a 52 week range of $7.68-$27.47.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
- Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Genuity Capital Markets, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
